Occupational allergic contact dermatitis caused by thebaine and oripavine

Dekeyser, Sam; Tomme, Mieke van; Boone, Barbara; Geel, Nanja van; Lapeere, Hilde

doi:10.1111/cod.12654

Cited by 6 publications

(3 citation statements)

References 4 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are reports of sensitization and contact dermatitis following occupational exposure to phenanthrene alkaloid opiates and their derivatives 4 . Reactions have been reported to formulations of: codeine, codeine dihydrophosphate, ethylmorphine, morphine, diacetylmorphine, naloxone, oxycodone, thebaine, oripavine and norhydroxymorphinone 4‐9 . To our knowledge this is the first reported case of contact allergy to nalmefene.…”

Section: Discussionmentioning

confidence: 80%

Occupational allergic contact dermatitis caused by nalmefene

et al. 2021

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 80%

Occupational allergic contact dermatitis caused by nalmefene

et al. 2021

View full text Add to dashboard Cite

“…Recently Dekeyser reported ACD caused by oripavine (tested at 5% pet., ethanol and aq.) for the first time, in a 35‐year‐old male working in a drug‐manufacturing plant who was also allergic to thebaine …”

Section: Introductionmentioning

confidence: 99%

“…for the first time, in a 35-year-old male working in a drug-manufacturing plant who was also allergic to thebaine. 13 Australia is one of the global players concerning the production and processing of poppy straw, but no cases of occupational ACD have been reported to date. 14 We report a case series of workers from an opioid-manufacturing facility who were referred to our clinic for patch testing over a 14-year period.…”

Section: Introductionmentioning

confidence: 99%

Occupational contact dermatitis caused by opioids: A case series

2019

View full text Add to dashboard Cite

Background: Opioid-manufacturing facility workers are at risk of developing occupational contact dermatitis.Objectives: To describe the causes of occupational allergic contact dermatitis caused by opioids in an opioid-manufacturing facility. Materials and Methods:A retrospective review was performed of patients assessed at the Occupational Dermatology Clinic in Melbourne, Australia from 2004 to 2017.Results: Fifteen workers from an opioid-manufacturing facility were assessed in our clinic over a period of 14 years. Of these, 11 individuals were diagnosed with occupational allergic contact dermatitis caused by opioids, with seven reacting to thebaine, five to morphine, four to norhydroxymorphinone, two to codeine, and two to oripavine. Two people were suspected of having immediate hypersensitivity reactions to opioids, including one who also had allergic contact dermatitis. Two patients were diagnosed with urticaria, aggravated at work. One patient was diagnosed with a non-occupational rash. Conclusions:We report a case series of workers with allergic contact dermatitis caused by opioids in a manufacturing facility. With greater awareness, including implementation of an educational programme and improved skin protection, the number of cases declined over time. Interestingly, norhydroxymorphinone had not been reported as an allergen before. Further testing is required to establish optimal patch test concentrations of all opiates. K E Y W O R D Scontact allergy, occupational allergic contact dermatitis, opioids, opioid-manufacturing facility, patch test, urticaria

show abstract